Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system.

BACKGROUND Hallucinations in patients with Parkinson disease (PD), occurring in about one third of those receiving long-term dopaminergic therapy, contribute to morbidity and mortality. In matched Chinese PD subjects with and without hallucinations, the presence of the -45 C/T locus in the cholecystokinin (CCK) gene, particularly when combined with the CCK receptor, CCKAR (cholecystokinin A receptor), C polymorphism, was associated with increased hallucination risk. Because CCK gene polymorphisms vary across ethnic groups, the presence of similar associations in white PD subjects merits investigation. OBJECTIVE To determine whether polymorphisms of CCK and CCK receptor genes are associated with hallucinations in white PD subjects. DESIGN Case-control study of PD subjects with and without chronic hallucinations matched for age and dopaminergic medication. Genomic DNA was analyzed for CCK, CCKAR, and CCKBR (cholecystokinin B receptor) polymorphisms by polymerase chain reaction. Genotype distributions and allele frequencies were compared between groups and in matched pairs. RESULTS Comparing matched pairs, we found more frequent representation of the CCK T allele in hallucinating PD subjects, although this finding was not statistically significant (P =.06). Of 5 cases with both CCK T and CCKAR C alleles, 4 were hallucinators. Cases and controls did not differ in CCKAR or CCKBR polymorphisms. CONCLUSIONS Our study supports a previous association of hallucinations in PD subjects with the CCK T allele and the combined CCK T and CCKAR C allele, suggesting that the CCK system may influence the development of hallucinations in PD subjects. The lower representation of the T allele in our white sample limited our statistical power. Further assessment of the T allele as a risk factor for hallucinations would include longitudinal study of nonhallucinators to detect the evolution of hallucinations relative to T allele frequency.

[1]  Jian Wang,et al.  Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease. , 2003, Pharmacogenetics.

[2]  Lorene M Nelson,et al.  Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. , 2003, American journal of epidemiology.

[3]  P. Taba,et al.  Incidence of Parkinson’s Disease in Estonia , 2003, Neuroepidemiology.

[4]  S. Leurgans,et al.  Prospective longitudinal assessment of hallucinations in Parkinson’s disease , 2001, Neurology.

[5]  T. Hansen Cholecystokinin gene transcription: promoter elements, transcription factors and signaling pathways , 2001, Peptides.

[6]  S. Harada,et al.  Polymorphisms of the CCK, CCKAR and CCKBR genes: an association with alcoholism study. , 2001, Journal of studies on alcohol.

[7]  D. Goldman,et al.  No association of CCK and CCKB receptor polymorphisms with alcohol dependence , 2001, Psychiatry Research.

[8]  S. Leurgans,et al.  Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. , 2001, Archives of neurology.

[9]  J. Friedman,et al.  Gender differences in the frequency and treatment of behavior problems in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[10]  X-Y Zhang,et al.  The CCK-A receptor gene possibly associated with positive symptoms of schizophrenia , 2000, Molecular Psychiatry.

[11]  H. Shiraishi,et al.  Novel polymorphisms of the human cholecystokinin A receptor gene: an association analysis with schizophrenia. , 2000, American journal of medical genetics.

[12]  G. Fénelon,et al.  Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. , 2000, Brain : a journal of neurology.

[13]  S. Harada,et al.  Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease , 1999, Clinical genetics.

[14]  J. Cummings,et al.  Range of neuropsychiatric disturbances in patients with Parkinson’s disease , 1999, Journal of neurology, neurosurgery, and psychiatry.

[15]  G. Hemmings,et al.  The CCK-A receptor gene possibly associated with auditory hallucinations in schizophrenia , 1999, European Psychiatry.

[16]  D. Maraganore,et al.  Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990 , 1999, Neurology.

[17]  T. Arinami,et al.  No association between C-45T polymorphism in the Sp1 binding site of the promoter region of the cholecystokinin gene and alcoholism , 1999, Psychiatry Research.

[18]  O. Lopez,et al.  Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. , 1998, Archives of neurology.

[19]  R. Noyes,et al.  Possible association of a cholecystokinin promotor polymorphism (CCK-36CT) with panic disorder. , 1998, American journal of medical genetics.

[20]  J. Sanchez-Ramos,et al.  Visual hallucinations associated with Parkinson disease. , 1996, Archives of neurology.

[21]  G. Stebbins,et al.  Mortality and hallucinations in nursing home patients with advanced Parkinson's disease , 1995, Neurology.

[22]  G. Stebbins,et al.  Risk factors for nursing home placement in advanced Parkinson's disease , 1993, Neurology.

[23]  Y. Agid,et al.  CCK-8-immunoreactivity distribution in human brain: selective decrease in the substantia nigra from parkinsonian patients , 1982, Brain Research.

[24]  R. Kahn,et al.  Dopamine, serotonin, and schizophrenia. , 1999, Advances in neurology.

[25]  Kahn Rs,et al.  Dopamine, serotonin, and schizophrenia. , 1999 .

[26]  T. Muramatsu,et al.  A new genetic variant in the Sp1 binding cis-element of cholecystokinin gene promoter region and relationship to alcoholism. , 1998, Alcoholism, clinical and experimental research.

[27]  N. Craddock,et al.  Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder , 1998, Molecular Psychiatry.

[28]  J. Crawley Cholecystokinin-dopamine interactions. , 1991, Trends in pharmacological sciences.

[29]  J. Crawley Cholecystokinin-dopamine intearctions , 1991 .